Teva Pharmaceutical Industries (NYSE:TEVA) versus Taysha Gene Therapies (NASDAQ:TSHA) Financial Analysis

Teva Pharmaceutical Industries (NYSE:TEVA) and Taysha Gene Therapies (NASDAQ:TSHA) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, analyst recommendations, institutional ownership, profitability and dividends.

Analyst Ratings

This is a summary of current recommendations and price targets for Teva Pharmaceutical Industries and Taysha Gene Therapies, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teva Pharmaceutical Industries	0	0	6	2	3.25
Taysha Gene Therapies	0	0	7	0	3.00

Teva Pharmaceutical Industries presently has a consensus target price of $24.7143, indicating a potential upside of 51.25%. Taysha Gene Therapies has a consensus target price of $8.1667, indicating a potential upside of 200.25%. Given Taysha Gene Therapies’ higher probable upside, analysts clearly believe Taysha Gene Therapies is more favorable than Teva Pharmaceutical Industries.

Volatility and Risk

Teva Pharmaceutical Industries has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500. Comparatively, Taysha Gene Therapies has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500.

Institutional & Insider Ownership

54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are owned by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are owned by insiders. Comparatively, 3.8% of Taysha Gene Therapies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Teva Pharmaceutical Industries and Taysha Gene Therapies”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teva Pharmaceutical Industries	$16.54 billion	1.13	-$1.64 billion	($0.16)	-102.13
Taysha Gene Therapies	$8.33 million	70.09	-$89.30 million	($0.34)	-8.00

Taysha Gene Therapies has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Taysha Gene Therapies, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Teva Pharmaceutical Industries and Taysha Gene Therapies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Teva Pharmaceutical Industries	-0.95%	46.10%	7.18%
Taysha Gene Therapies	-1,201.08%	-104.93%	-50.09%

Summary

Taysha Gene Therapies beats Teva Pharmaceutical Industries on 8 of the 15 factors compared between the two stocks.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin’s lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington’s disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.